Atossa reports Q3 2026 results, outlines CVR tied to future priority review voucherNov 10Quarterly updateAtossa Therapeutics, Inc.endoxifen
Atossa executes CVR agreement tied to future priority review voucher valueOct 9Regulatory milestoneAtossa Therapeutics, Inc.
Atossa plans stapled CVR tied to rare pediatric disease review voucherSep 29Regulatory milestoneAtossa Therapeutics, Inc.
Atossa reports Q2 2026 results, completes enrollment in EVANGELINE trialAug 7Quarterly updateAtossa Therapeutics, Inc.endoxifen